| Literature DB >> 25572180 |
Ling Zeng1, Juan Du2, Wei Gu3, An-qiang Zhang4, Hai-yan Wang5, Da-lin Wen6, Lin Qiu7, Xue-tao Yang8, Jian-hui Sun9, Mao Zhang10, Jiang Hao11, Jian-xin Jiang12.
Abstract
INTRODUCTION: The receptor for advanced glycation end products (RAGE) is a transmembrane receptor of the immunoglobulin superfamily, it plays pivotal roles in the pathogenesis of sepsis in several ways. Our previous study showed that rs1800625 (-429T/C) revealed a strong clinical relevance with sepsis morbidity rate and multiple organ dysfunction syndrome (MODS) in patients with major trauma. In this study, we enlarged the sample size, added two validation populations and examined the expression of RAGE on the surface of peripheral leukocytes to ex vivo lipopolysaccharide (LPS) stimulation in subjects with different genotypes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25572180 PMCID: PMC4310192 DOI: 10.1186/s13054-014-0727-2
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Primers and PCR conditions
|
|
|
|
|
|
|---|---|---|---|---|
| rs1800625 | F: *bio-TCTTTTTTCCCTGGGTTTAGTTGA | GAGAGAAACCTGTTTGG | AA/GCTTC | 60°C |
| R: ATAGGGTTCAGGCCAGACTGTTGT |
*biotin labeling.
Overall clinical characteristics of patients with major trauma
|
|
| ||
|---|---|---|---|
|
|
|
| |
| Age (yrs) | 41.1 ± 13.4 (18-65) | 42.5 ± 12.0 (19-65) | 37.6 ± 12.5 (18-65) |
| Male/female, n | 672/165 | 266/74 | 282/85 |
| Injured body regions, n (%) | |||
| Head, n | 458 (54.7) | 248 (72.9) | 225 (61.3) |
| Thorax, n | 513 (61.2) | 209 (61.5) | 186 (50.7) |
| Abdomen, n | 389 (46.4) | 118 (34.7) | 105 (28.6) |
| Extremities, n | 425 (50.8) | 179 (52.6) | 196 (53.4) |
| Number of regions injured, n (%) | |||
| One, n | 435 (52.0) | 146 (42.9) | 157 (42.8) |
| Two, n | 267 (31.9) | 129 (37.9) | 131 (35.7) |
| Three or above, n | 135 (16.1) | 65 (19.1) | 79 (21.5) |
| ISS | 22.3 ± 9.4 | 21.7 ± 7.7 | 21.3 ± 9.2 |
| ≥16, <25, n (%) | 510 (60.9) | 197 (57.9) | 228 (62.1) |
| ≥25, n (%) | 327 (39.1) | 143 (42.1) | 139 (37.9) |
| Organ dysfunction, n (%) | |||
| One, n | 268 (32.2) | 112 (32.9) | 125 (34.1) |
| Two, n | 121 (14.5) | 56 (16.5) | 51 (13.9) |
| Three or above, n | 41 (4.9) | 23 (6.8) | 35 (9.5) |
| Sepsis, n (%) | 346 (41.3) | 129 (37.9) | 130 (35.4) |
| Source of infection, % | |||
| Respiratory tract infection | 41.6 | 39.7 | 43.2 |
| Primary bloodstream infection | 21.5 | 24.1 | 19.9 |
| Urinary tract infection | 16.2 | 11.2 | 12.1 |
| Catheter-associated infection | 10.9 | 9.1 | 9.3 |
| Wound infection | 7.4 | 9.1 | 10.1 |
| Others* | 2.4 | 6.8 | 5.4 |
| Pathogens, % (positive blood cultures) | |||
| Gram-negative | 22.3 | 25.7 | 29.5 |
| Gram-positive | 17.6 | 13.2 | 12.8 |
| Fungi | 2.8 | 3.5 | 3.6 |
| Mixed Gram-negative and -positive | 5.9 | 7.5 | 8.5 |
| Negative blood cultures | 54.0 | 55.0 | 57.0 |
ISS, Injury Severity Score.
Distribution of rs1800625 of the RAGE gene among trauma patients in the three cohorts
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||
|
| 837 | 14.2 | 12.2 | 620 | 195 | 22 | 0.16 |
|
| 340 | 10.7 | 271 | 65 | 4 | 0.96 | |
|
| 367 | 14.9 | 269 | 86 | 12 | 0.12 | |
Clinical relevance of rs1800625 among trauma patients in the three cohorts
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| TT | 620 | 40.8 ± 13.1 | 494/126 | 22.6 ± 9.3 | 275 (46.8%) | 6.9 ± 2.2 |
| TC | 195 | 41.9 ± 14.5 | 157/38 | 21.5 ± 9.7 | 65 (33.3%) | 6.0 ± 2.0 | |
| CC | 22 | 41.0 ± 11.4 | 21/1 | 20.0 ± 9.4 | 6 (27.3%) | 5.2 ± 1.7 | |
| a1 | a2, b1 | ||||||
|
| TT | 271 | 42.3 ± 12.7 | 212/59 | 21.7 ± 7.7 | 113 (41.7%) | 7.5 ± 2.5 |
| TC | 65 | 42.8 ± 16.2 | 50/15 | 21.9 ± 7.6 | 15 (23.1%) | 6.8 ± 2.6 | |
| CC | 4 | 45.8 ± 19.8 | 4/0 | 18.8 ± 6.5 | 1 (25.0%) | 5.9 ± 3.1 | |
| a3 | a4 | ||||||
|
| TT | 269 | 37.4 ± 12.5 | 208/61 | 21.3 ± 9.0 | 103 (38.3%) | 7.2 ± 2.0 |
| TC | 86 | 38.7 ± 12.0 | 64/22 | 20.8 ± 9.8 | 24 (27.9%) | 6.3 ± 2.1 | |
| CC | 12 | 33.8 ± 14.4 | 10/2 | 24.8 ± 8.7 | 3 (25.0%) | 5.8 ± 2.6 | |
| a5 | a6 |
a: dominant effect (variant homozygotes + heterozygotes vs. wild homozygotes) as analyzed by ANCOVA, a1 P = 0.002, a2 P = 0.001, a3 P = 0.003, a4 P = 0.032, a5 P = 0.047, a3 P = 0.016, a4 P = 0.042, a5 P = 0.012, a6 P = 0.026; b: recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes) as analyzed by ANCOVA, b1 P = 0.032. ISS. Injury Severity Score; MODS, multiple organ dysfunction syndrome.
Figure 1Association of the rs1800625 with LPS-induced expression of RAGE protein. The whole blood samples were collected from 42 healthy volunteers (TT: N = 32, TC: N = 8, CC: N = 2). The RAGE expression on the peripheral leukocytes was assayed using flow cytometry and was presented as MFI. One-way ANOVA was used to assess statistical significance. P = 0.009 for dominant association (CC + TC vs. TT). ANOVA, analysis of variance; LPS lipopolysaccharide; RAGE, the receptor for advanced glycation end products.